Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The AL Amyloidosis Market?

In recent times, there has been a considerable expansion in the size of the al amyloidosis market. The market is forecasted to grow from a value of $3.11 billion in 2024 to approximately $3.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the remarkable growth during the historic period encompass increasing knowledge of al amyloidosis among healthcare professionals, a surge in al amyloidosis cases, a growing older population, the proliferation of diagnostic centers, and advancements in cardiac imaging.

In the upcoming years, the al amyloidosis market is predicted to experience swift expansion. The market is forecasted to increase to $5.68 billion in 2029 with a 12.8% compound annual growth rate (CAGR). The projected growth during this period can be credited to a rise in the occurrence of mutations in blood cell DNA, the expansion of healthcare infrastructure, an increasing number of multiple myeloma cases, the unveiling of combined therapies, and a higher use of high-dose chemotherapy. Significant trends during this forecast period will include progress in diagnostic techniques, technological advancements in drug delivery, improvements in blood tests, the evolution of targeted therapies, and the utilization of artificial intelligence (AI) in diagnosis.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp

What Core Drivers Are Expected To Influence The AL Amyloidosis Market?

The escalation in the prevalence of plasma cell disorders is predicted to fuel the expansion of the AL amyloidosis market. Plasma cell disorders are pathologies in which abnormal plasma cells create an overabundance of atypical antibodies, potentially leading to organ damage. Factors such as aging populations, increased lifespan, and advancements in diagnosis technologies are contributing to the rising occurrence of these disorders. AL amyloidosis originates from plasma cell disorders, primarily as a result of too much production of abnormal light chain proteins. These could lead to amyloid deposit build-up in organs and tissues, worsening the impact of plasma cell dyscrasias. For example, in August 2024, The American Cancer Society, a US-based nonprofit organization, reported that around 35,780 new cases of multiple myeloma (19,520 in men and 16,260 in women) are anticipated to be detected in 2024. Additionally, approximately 12,540 deaths (7,020 in men and 5,520 in women) are projected. Hence, the escalating prevalence of plasma cell disorders is pushing the growth of the AL amyloidosis market.

What Are The Main Segment Classifications In The AL Amyloidosis Market?

The al amyloidosismarket covered in this report is segmented –

1) By Treatment: Chemotherapy; Supportive Care; Surgery; Stem Cell Transplant; Targeted Therapy

2) By Drugs: Transthyretin Transport Inhibitor; Immunomodulatory Drugs; Monoclonal Antibodies; Proteasome Inhibitors; Other Drugs

3) By Route Of Administration: Intravenous; Oral

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Chemotherapy: Conventional Chemotherapy Agents; High-Dose Chemotherapy

2) By Supportive Care: Pain Management; Organ-specific Supportive Care (Cardiac, Renal)

3) By Surgery: Organ Transplantation; Debulking Surgery

4) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant

5) By Targeted Therapy: Monoclonal Antibodies; Proteasome Inhibitors; Kinase Inhibitors

How Are Industry Trends Steering The Expansion Of The AL Amyloidosis Market?

Key players in the AL amyloidosis market are shifting their focus towards introducing revolutionary therapies like the next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy to enhance the effectiveness of treatments and patients’ health results. This next-generation BCMA-directed CAR T-cell therapy is an evolved form of immunotherapy where a patient’s T cells are engineered to aim at and attack BCMA present on the surface of cancer cells, especially in multiple myeloma. For example, Immix Biopharma Inc, a biopharmaceutical firm based in the US, obtained approval in September 2033 from the U.S. Food and Drug Administration (FDA) for NXC-201 as a treatment for a critical blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201, a next-generation CAR-T cell therapy, undergoes clinical trials for treating amyloid light chain (AL) amyloidosis and has demonstrated promise with a hematological response rate of 100% and progressive organ improvements in patients who had been unresponsive to previous treatments.

Which Companies Are Contributing Significantly To The AL Amyloidosis Market Growth?

Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Which Region Holds The Greatest Opportunity For AL Amyloidosis Market Expansion?

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20710&type=smp

Browse Through More Reports Similar to the Global AL Amyloidosis Market 2025, By The Business Research Company

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Plasmas Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/plasmas-therapy-global-market-report

Mycoplasma Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model